The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life.


Journal

Rhinology
ISSN: 0300-0729
Titre abrégé: Rhinology
Pays: Netherlands
ID NLM: 0347242

Informations de publication

Date de publication:
01 Oct 2019
Historique:
pubmed: 19 7 2019
medline: 14 11 2019
entrez: 19 7 2019
Statut: ppublish

Résumé

Chronic rhinosinusitis (CRS) significantly affects health-related quality of life (HRQoL). Few multinational observational studies have evaluated the impact of CRS with nasal polyps (CRSwNP) on patients’ HRQoL. This study aimed to assess HRQoL outcomes (including analyses by disease severity and impact of comorbidities and refractory disease) in CRSwNP patients from a large European database. Data were analysed from the Global Allergy and Asthma European Network (GALEN) Rhinosinusitis Cohort, including sociodemographic data, patient-reported disease severity (visual analogue scale), and scores on the 36-Item ShortForm Health Survey (SF-36) questionnaire. Differences in mean SF-36 scores were evaluated between patients with CRSwNP and population norms and between subgroups of interest (disease severity, comorbidity, and refractory disease, defined by a history of sinonasal surgery). Patients with CRSwNP (N = 445) had significantly lower mean SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores vs population norms, demonstrating that CRSwNP negatively affects HRQoL. The presence of comorbidities affected HRQoL, as shown by significant differences in PCS scores in patients with asthma or non-steroidal antiinflammatory drug-exacerbated respiratory disease, compared with patients without asthma. Patients with moderate-to-severe disease had significantly lower PCS scores than patients with mild disease. Severe disease had a significant impact on MCS score. History of surgery had a clinically meaningful negative effect on HRQoL compared with no history of surgery. CRSwNP patients have significantly lower HRQoL compared with population norms. The impact is greater in patients with greater disease severity, comorbidities, or refractory disease.

Sections du résumé

BACKGROUND BACKGROUND
Chronic rhinosinusitis (CRS) significantly affects health-related quality of life (HRQoL). Few multinational observational studies have evaluated the impact of CRS with nasal polyps (CRSwNP) on patients’ HRQoL. This study aimed to assess HRQoL outcomes (including analyses by disease severity and impact of comorbidities and refractory disease) in CRSwNP patients from a large European database.
METHODOLOGY METHODS
Data were analysed from the Global Allergy and Asthma European Network (GALEN) Rhinosinusitis Cohort, including sociodemographic data, patient-reported disease severity (visual analogue scale), and scores on the 36-Item ShortForm Health Survey (SF-36) questionnaire. Differences in mean SF-36 scores were evaluated between patients with CRSwNP and population norms and between subgroups of interest (disease severity, comorbidity, and refractory disease, defined by a history of sinonasal surgery).
RESULTS RESULTS
Patients with CRSwNP (N = 445) had significantly lower mean SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores vs population norms, demonstrating that CRSwNP negatively affects HRQoL. The presence of comorbidities affected HRQoL, as shown by significant differences in PCS scores in patients with asthma or non-steroidal antiinflammatory drug-exacerbated respiratory disease, compared with patients without asthma. Patients with moderate-to-severe disease had significantly lower PCS scores than patients with mild disease. Severe disease had a significant impact on MCS score. History of surgery had a clinically meaningful negative effect on HRQoL compared with no history of surgery.
CONCLUSIONS CONCLUSIONS
CRSwNP patients have significantly lower HRQoL compared with population norms. The impact is greater in patients with greater disease severity, comorbidities, or refractory disease.

Identifiants

pubmed: 31318362
pii: 1925
doi: 10.4193/Rhin19.158
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

343-351

Auteurs

A Khan (A)

Sanofi, Chilly Mazarin, France; Ghent University Hospital, Ghent, Belgium.

T M T Huynh (TMT)

Sanofi, Chilly Mazarin, France.

G Vandeplas (G)

Ghent University Hospital, Ghent, Belgium.

V N Joish (VN)

Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.

L P Mannent (LP)

Sanofi, Chilly Mazarin, France.

P Tomassen (P)

Ghent University Hospital, Ghent, Belgium.

T van Zele (T)

Ghent University Hospital, Ghent, Belgium.

L-O Cardell (LO)

CLINTEC, Karolinska Institutet, Stockholm, Sweden.

J Arebro (J)

CLINTEC, Karolinska Institutet, Stockholm, Sweden.

H Olze (H)

Charite-Universitatsmedizin Berlin, Berlin, Germany.

U Forster-Ruhrmann (U)

Charite-Universitatsmedizin Berlin, Berlin, Germany.

M L Kowalski (ML)

Medical University of Lodz, Lodz, Poland.

A Olszewska-Ziaber (A)

Medical University of Lodz, Lodz, Poland.

W Fokkens (W)

Academic Medical Center, Amsterdam, the Netherlands.

C van Drunen (C)

Academic Medical Center, Amsterdam, the Netherlands.

J Mullol (J)

Hospital ClÃ-nic â€" IDIBAPS, CIBERES, Barcelona, Spain.

I Alobid (I)

Hospital ClÃ-nic â€" IDIBAPS, CIBERES, Barcelona, Spain.

P W Hellings (PW)

University Hospitals Leuven, Leuven, Belgium.

V Hox (V)

University Hospitals Leuven, Leuven, Belgium.

E Toskala (E)

Temple University School of Medicine, Philadelphia, PA, USA.

G Scadding (G)

Royal National Throat, Nose and Ear Hospital, London, UK.

V Lund (V)

Royal National Throat, Nose and Ear Hospital, London, UK.

C Bachert (C)

Ghent University Hospital, Ghent, Belgium; CLINTEC, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH